Results 181 to 190 of about 207,710 (257)

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Unmasking orthostatic hypotension after cellular therapy: risk factors, implications, and clinical significance. [PDF]

Support Care Cancer
Vazquez-Urrutia JR, Santucci J, Modgil P, Lal A, Inoue Y, Zimmerman J, Woodworth R, Knol K, Hess E, Jordan J, Stover J, Rekawek E, Cioccio J, Rakszawski K, Songdej N, Nickolich M, Zheng H, Naik S, Ehmann C, Silar B, Vajdic C, Bartram D, Mineish S, Minagawa K.   +23 more
europepmc   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

British Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova, Yoana Lilova, Alexander Oscar, Alina Levi, Maria Kamusheva, Guenka Petrova   +5 more
wiley   +1 more source

Feasibility of Mobile Single-Lead Electrocardiogram Screening for Atrial Fibrillation: Multicenter Cross-Sectional Study. [PDF]

JMIR Cardio
Fenske R, Rossa D, Butter C, Muehlensiepen F, Nübel J, Meretz D, Ritter O, Spethmann S, Mantke R, Zerbaum M, Draheim N, Lindenberg-Krause N, Haase-Fielitz A.   +12 more
europepmc   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Etiology and Selected Multidrug-Resistance Patterns in Urinary Bacterial Isolates: A Comparative Analysis of Outpatients and Inpatients at a Tertiary Hospital in Mexico City. [PDF]

Microorganisms
Paredes-Cervantes V, Rosel-Pech C, Rojas-Osornio SA, Reyes-Serrato E, López-Pelcastre L, Manuel-Apolinar L, Montiel-Cervantes LA, Molina-López J, Cruz-Domínguez MP, Rendón-Maldonado JG, Minauro-Sanmiguel F, Ruiz-Tachiquín ME, Vázquez-Vega S, Tesoro-Cruz E.   +13 more
europepmc   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source